Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00003805 · ClinicalTrials.gov registry record · Phase 3
Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count
A Phase 3 study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- Completed
- Registry status
- Phase 3
- Development phase
- 859
- Enrollment target
NCT00003805: Completed Phase 3 study, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
NCT00003805 is a Phase 3 study that has completed, run by European Organisation for Research and Treatment of Cancer - EORTC. The registered enrollment target is 859 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00003805, a Phase 3 study, has completed, sponsored by European Organisation for Research and Treatment of Cancer - EORTC.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 859 participants
- Enrollment target
Study Summary
RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomized phase III trial to study the effectiveness of piperacillin-tazobactam with or without vancomycin in reducing fever in patients who have leukemia, lymphoma, or Hodgkin's disease.
Interventions
- DRUG vancomycin
- DRUG piperacillin sodium
- DRUG piperacillin-tazobactam
- DRUG tazobactam sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 859 participants |
| Start Date | 1997-11 |
| Phase | Phase 3 |
What the finished NCT00003805 record still lists
NCT00003805 is an interventional study that assigns participants to a tested intervention. The registered 859 participants enrollment target is mid-sized for trials with a published cap, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (11% higher).
The record links to 0 conditions, and to 4 interventions - of which vancomycin is the first listed.
NCT00003805 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00003805 about?
NCT00003805 is a clinical study titled "Prevention of Infection in Patients With Hematologic Cancer and Persistent Fever Caused by a Low White Blood Cell Count". RATIONALE: Antibiotic therapy may prevent the development of infection in patients with hematologic cancer and the persistent fever caused by a low white blood cell count. It is not yet known which regimen of antibiotics is most effective in preventing infection in these patients. PURPOSE: Randomiz...
What is the current status of trial NCT00003805?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 859 participants. The study started on 1997-11.
What interventions are being tested in trial NCT00003805?
The interventions under investigation include: vancomycin (DRUG), piperacillin sodium (DRUG), piperacillin-tazobactam (DRUG), tazobactam sodium (DRUG).
Who is sponsoring clinical trial NCT00003805?
This trial is sponsored by European Organisation for Research and Treatment of Cancer - EORTC, which has 15 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00003805's enrollment target sits among peer trials
859 383rd of 2000 higher than 1,618 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04541381 · 860 participants · NA
The PhOCus Trial: Implementation of Pharmacogenomic Testing in Oncology Care
- NCT05211895 · 860 participants · Phase 3
A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC
- NCT06161025 · 860 participants · Phase 2
A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer
- NCT06541574 · 860 participants · Phase 2
Prevention of ProliFerative Vitreoretinopathy with Intravitreal MethotreXate in Primary Retinal DEtachment Repair (FIXER) Trial
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia